Email Updates

Search form

You are here

AVAC's Blog: P-Values

  • Charles Brown reflects on the important role of advocates in prevention research and what they need to succeed. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 30, 2014
    Charles Brown, 2014 AVAC Advocacy Fellow
  • Yvette Raphael critiques researchers' efforts to engage young women at the 2014 HIV Research for Prevention (HIV R4P) conference. She challenges how researchers talk about women "lying" about adherence and expresses frustration at the difficulty of getting these researchers to participate in a conversation about this. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 30, 2014
    Yvette Raphael, 2014 AVAC Advocacy Fellow
  • Greetings from the third day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos

    October 30, 2014
  • Definate Nhamo and Teresia Njoki Otieno report on key conversations around women's HIV prevention. They discuss research findings on adherence in ARV-based prevention trials and the evolving body of evidence on hormonal contraceptive use and HIV risk. They also highlight the perspectives of young women who participated in the conference. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 29, 2014
    Teresia Njoki Otieno, 2014 AVAC Advocacy Fellow
    Definate Nhamo, 2014 AVAC Advocacy Fellow
  • PrEP took centerstage at the morning plenaries at HIV R4P—and while the talks were going on, the French research agency announced that the IPERGAY trial of intermittent ("on demand") PrEP would be discontinuing randomization and placebo control after strong preliminary evidence of efficacy. This blog post gives a look at both developments.

    October 29, 2014
    AVAC
  • Greetings from the second day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 29, 2014
  • Eric Mcheka reacts to a presentation by Mitchell Warren during an advocates' workshop. This post was written for the WhatsUpHIV blog, which reported in real time on the 2014 HIV Research for Prevention conference in Cape Town, South Africa.

    October 28, 2014
    Eric Mcheka, 2014 AVAC Advocacy Fellow
  • In this post (first appearing on Breakthroughs, a blog from GHTC), Emily Donaldson—program coordinator at AVAC—and Tom Harmon—senior policy analyst at the International AIDS Vaccine Initiative (IAVI)—write about the state of HIV prevention research funding as the first-ever conference devoted solely to HIV prevention research and development (R&D) takes place in Cape Town, South Africa, this week.

    October 28, 2014
    General
    Emily Donaldson - AVAC
    Tom Harmon - IAVI
  • Greetings from the first official day of the HIV R4P conference! Each day AVAC will be providing a dispatch with highlights from the conference. Read on for information about the plenary speeches and individual sessions. And we are tweeting all the latest news and photos. Follow us!

    October 28, 2014
    AVAC
  • Clinical trials can only achieve their goals if participants use the product. A trial looking at safety or efficacy can’t gather information or draw conclusions if the trial volunteers choose not to follow the protocol—whether it is taking a drug, using a gel or returning for a follow-up injection of a vaccine.
    October 27, 2014
    AVAC

Pages